Publicacións nas que colabora con Patricia Aspichueta Celaa (21)

2024

  1. Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

    Hepatology

  2. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  3. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2022

  1. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

    Hepatology, Vol. 76, Núm. 6, pp. 1617-1633

  2. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

  3. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

  4. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

  5. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

  6. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  3. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  4. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

    United European Gastroenterology Journal, Vol. 9, Núm. 7, pp. 848-859

  5. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  6. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

  7. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25